Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you, Operator, and welcome everyone to BONESUPPORT's Q4 and full year 2025 results call. My name is Torbjörn Sköld. I'm the CEO of BONESUPPORT. And with me here today is our CFO. Håkan Johansson and together we will use the next 25 minutes to guide you through the Q4 presentation and then open the line for questions. But before we start the presentation, I would like to draw your attention to the disclaimers covering any forward-looking statements that we will make today. So let's look at the financial and operational highlights from the quarter. Q4 was another strong quarter with solid execution across the business. Net sales came in at 313 million SEK, corresponding to a growth of 22% versus Q4 2024. Sales growth at constant exchange rates was 36%, showing that there was a continued strong currency impact on our figures for the quarter. Our adjusted operating results, excluding incentive program effects, were 81 million SEK, corresponding to an adjusted operating margin of 26%. Reported operating results were 82 million SEK, and we saw solid cash generation with operating cash flows reaching 54 million SEK. We continue to see strong traction for CERAMENT G in the US, where both new accounts and increased use among current users contributed to the strong progress. CERAMENT G sales in the US reached 207 million SEK for the quarter, compared to 154 million SEK in the same period the year before. In EUROW, we saw strong momentum, which more than offset the negative effects of the German market reforms, and during the quarter, we also advanced our regulatory pipeline, as communicated in early December. The FDA submission for CERAMENT V has now been transferred from the 510(k) pathway to the De Novo process. This change reflects the FDA's assessment that CERAMENT V may constitute an entirely new product category, like CERAMENT G in 2022, and positions us for a stronger long term market entry. In addition, we initiated the early stage launch of CERAMENT for spine in the US, an important step as we continue expanding our portfolio of indications and applications. I will come back to that later in my presentation. Now let's move to the sales development. The chart shows total Last Twelve Months. Reported sales in Swedish Krona by quarter since 2019. The data is presented in stacked bars per region and product category. As you can see, the launch momentum for CERAMENT G in the US is exceptionally strong. Given that we keep bringing new, strong clinical studies and opening up new markets, market segments and new indications. A product like CERAMENT G will remain in launch phase for many years to come. However, throughout 2025, we have seen a strong impact from the US dollar to Swedish krona depreciation. Last Twelve Months growth in Q4 of 31% in the graph corresponds to an even stronger 40% at constant exchange rates. So, most of this quarter-over-quarter deceleration in last twelve months' growth was evident. Sales are due to a strong currency impact on us. The last twelve months was flat year over year in constant currency. In total, the antibiotic-eluting CERAMENT grew by 54% for the last 12 months, as of the quarter, in constant currency. Next slide please. In the US, sales amounted to 259 million SEK, representing a growth of 40% at constant exchange rate. There was some general variability during the quarter due to the number of working days. At the same time, we continue to experience strong growth of CERAMENT G, driven by both increased access through new accounts and new surgeons, as well as wider adoption among existing accounts and surgeons. In trauma, we see expanding access and adoption in Level One trauma centers, which is an important validation of CERAMENT G for treating complex infections and bone voids in the most demanding clinical environments. There are roughly 250 Level I Trauma Centers in the US. These are the very large and most important centers for advanced trauma treatments. And at the end of 2024, we had sold CERAMENT to 15 of these. We had sold to more than 140 level one trauma centers. That said, actual use is evolving gradually as trauma surgeons carefully assess and evaluate new products before they become part of regular use. And remember that full healing and evaluation of a trauma patient can take more than six months. As part of our mission to modernize an outdated standard of care in the US, we have successfully opened one market segment after another. We started in foot and ankle, followed by trauma and now moving into revision arthroplasty. Interest continues to grow for CERAMENT in revision arthroplasty and periprosthetic joint infections, two areas where the clinical needs remain substantial and where the evidence supporting our antibiotic eluting technology has resonated strongly with surgeons. We've built a solid foundation for our spine strategy over the past quarters by establishing distributed coverage and preparing for the market. In Q4, we initiated the early stage launch of CERAMENT BVF in Spinal Procedures. With distributors now actively engaging spine surgeons across both existing and new partnerships. As this is a new clinical segment for us. More clinical data is needed to support broader market penetration longer term. Importantly, the performance of CERAMENT in spine will help confirm the value proposition for the CERAMENT platform, which will pave the way for the future CERAMENT G launch. We have made strong progress in evaluating and preparing the regulatory pathway, and will share more on the path forward at our Capital Markets Day this spring. Now let's turn to Europe. Next slide please. Sales in Europe and the rest of the world came in at 54 million SEK, representing 18% growth at constant exchange rates. Sales in Europe continued to be influenced by the same dynamics as observed in Q3, meaning that hospital reforms and surgical protocol programs in Germany remained prevalent. They're still impacting our sales. However, direct markets excluding Germany delivered at normal growth rates. And by the way, when we say normal growth rates, we mean normal for CERAMENT. The growth rates that we see outside Germany are 4 to 5 times higher than growth rates for the market in general. Furthermore, hybrid markets in Southern Europe, Australia and Canada are performing strongly. We see positive traction from the investments made during the first half of 2025, reflected in improved sales performance. Now I'll leave a deep dive into the numbers to Håkan.
Thank you, Torbjörn.
Net sales improved from 257 to 312.5 million, representing a 22% growth in reported sales, or 36% at constant exchange rates. Torbjörn has already spoken about the solid performance in especially the US and the major drivers behind the sales growth. But as the weak US. dollar somewhat hides a continued strong trajectory in the US, I would like to share the US performance. The sales performance is shown in US dollars. CERAMENT G is the growth driver in the US, and this slide shows the quarterly CERAMENT sales in the US in US dollars with continued solid performance. Quarter to quarter. The number of working days in each period varies. Sales are impacted, especially in Q4, which is affected by both Thanksgiving and the holiday season over Christmas and New Year's. Taking this into consideration, a strong net sales per working day is noted during the quarter when looking at the orange line in the presentation. The contribution from the US segment improved by 30 million and amounted to 120.2 million. The improved contribution relates to increased sales, net of increased costs. Selling and marketing expenses during the quarter amounted to 128 million, compared with 108.8 million in the previous year, of which sales commissions to distributors and fees amounted to 85 million, compared with 69.6 million in the same quarter last year. From the graph at the bottom of the screen showing net sales as bars and gross margin as the orange marker. It can be noted that the gross margin remained stable and strong at around 95%, with a minor decline in the period following a gradual impact from US tariffs in Europe and the rest of the world. A contribution of 11.9 million was reported, compared with 12.8 million the previous year. Selling and marketing expenses increased by 4.9 million, including 3.6 million. Related to the previously communicated commercial investments in the so-called Euro Booster program, from the lower growth and as indicated by the orange marker, a minor drop in gross margin can be noted, mainly impacted by the market mix. Selling expenses, excluding sales commission and fees, increased by 8.6 million, mainly in staffing expenses. Of which 3.6 million relates to the so-called euro booster. The increase from Q3 this year relates to seasonality, as Q4 is usually intense in terms of congresses and marketing activities. R&D remains focused on the execution of strategic initiatives such as the application studies and spine procedures, and the Market Authorization Submission for CERAMENT V in the US. The expense for the quarter includes submission fees and other additional expenses related to the change in regulatory pathway for CERAMENT V in the US. And finally, administrative expenses, excluding the effects from long-term incentive programs, reported a small increase for the period, of which 2.8 million related to the CEO succession. The reported operating result amounted to 8.1 million, despite unfavorable currency effects, totaling 2.9 million. And I will come back to this in a later slide. The newly introduced tariffs in the United States had a greater impact on costs in the quarter. The full effect of the current 50% tariff will result in a 0.8% impact on US gross margins, which will come gradually with full effect late 2026. The difference between adjusted and reported operating result is costs regarding our long-term incentive programs, amounting to a negative expense of 0.5 million in the quarter, compared with an expense of 13.7 million in the previous year. As you can see from the previous slide, the reduced costs are due to the drop in share price. Operating cash flow remains solid, with an increase in accounts receivables at the end of the year, mainly as customer payments seem to have been deferred to after the holidays. During the period, the Swedish krona has continued to strengthen against the US dollar. Other operating income and expenses therefore contain foreign exchange gains and losses from the translation of the group's receivables and liabilities in foreign currency, amounting to -2.9 million. The graph on this slide shows, with gray bars, how the relationship between the US dollar closing rate and the Swedish krona has varied over time. This is read out on the right axis. The blue dotted line, read out on the left axis, shows adjusted operating result. The adjusted operating result, excluding translation exchange effects, is the orange line and gives a more comparable view of the underlying trend in operating results. In the table below the graph, you can see the FX adjusted operating margin of close to 27% in the period, compared with 22.6% in the same quarter last year. And with this, I hand back to you.
Thank you. Håkan. So to summarize, Q4 2025 sales grew by 36% in constant currencies, reflecting steady and consistent progress. Adjusted operating margin reached 26%. Cash flow also remained robust, underscoring the strength and scalability of the business. I'm convinced that the most exciting part of our journey still lies ahead. And, as I said, to provide a clearer view of what that journey will look like. We will host a Capital Markets Day in Stockholm on the 26th of May this year, which you are, of course, all welcome to join now. Happy to open up the line for questions.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Victor Sundberg from Nordica. Please go ahead.
Yes. Hi. Thanks for taking my questions. My first question is on CERAMENT G in the US. As you mentioned, year-over-year growth in the quarters is decreasing. But it's mostly FX related, as you mentioned. But when you say 'mostly', does anything indicate an underlying headwind in the U.S.? in 2025? And also, what kind of underlying growth have you baked into your guidance for 2026, and how does that growth compare to 2025 growth in constant exchange rates? That's my first question. Thanks.
So thank you, Victor. I think that the takeaway from the report is twofold; one point is somewhat against expectations. We see a continued strong trajectory with CERAMENT G in the US, especially when looking at sales on average per working day. Taking that in combination, also what Torbjörn mentioned in terms of access to level one trauma centers, etc., and of course, both these aspects are aspects that have been included in our estimates and our work ahead of presenting the guidance for 2026. So we remain very optimistic on the continued opportunities for CERAMENT in the US.
Indeed. And I would like just to add to that, when we look at the performance in 2025 and in Q4, we look at two important aspects of where the growth comes from in general and also particularly in CERAMENT. And it relates to new accounts gaining access, as well as increasing the adoption within existing accounts. So, both these two levers, and depending on whether it's at the surgeon level, account level, IDM level, or DPO level, we measure and track them. And what's important for us is to make sure that we have a healthy growth, not only in access but also in adoption. We want to have it in both. And what we've seen throughout 25, as well as in quarter four, is that we have a really healthy adoption. And the growth rate on the total stems from both of those legs contributing almost to equal size, which is very positive. And that goes generally as well as for CERAMENT G. In particular, we've already talked about the level one trauma center adoption rate. In 2024, we sold to 15 of them, and in 2025 we have sold to more than 140. And what we mean by 'sell' is that we sell at least one product. So again, it's very, very early phase, but it's a really strong indication for us at least that we get access. We get interest among orthopedic surgeons, among the infectious disease doctors. And we have a really strong foundation to build on in trauma. For many, many years to come. So that's on trauma. The next segment that we've just started to scratch the surface on is revision arthroplasty. Early days. We have very convincing evidence, but it's a pilot study from Charité indicating very strong results for CERAMENT G in revision arthroplasty. So this also looks very promising. For both the short, medium and long term in the US. On top of those areas, specifically trauma and revision arthroplasty, we have foot and ankle, which we still see a lot of potential to continue to build on. As we develop more application techniques as we come out with more clinical studies. And then, of course, very exciting for us is when we get FDA approval for CERAMENT V, as we transitioned from a 510(k) process to a De Novo process, which in the long term is actually very positive for us. And that, of course, adds to the total mix. We do not expect a lot of cannibalization on CERAMENT G from CERAMENT V. We believe that that will be somewhat immaterial in the grand scheme of things. So I think that paints the picture of our outlook short, medium and long term for CERAMENT G in the US.
Okay, thanks. And maybe in Germany and the UK also, that's been a bit of a drag on growth in 2025. How much of this drag is baked into your guidance for 2026? And when do you expect this to turn around? And any sense of what the underlying demand is if funding issues would be a bit better in these countries. Again, if you just look at it from Q3 to Q4 in US dollars and not taking workdays into consideration, it is a slight growth in Q4 to Q3.
So we communicated already when released in Q3 that we do not expect some swift recovery. In Germany, we think that Germany will remain somewhat sluggish throughout 2026. However, when it comes to the UK, and what we also observed in Q4, we expect the situation in the UK to normalize, in the sense that surgeries where CERAMENT is used are coming back to normal levels. And the surgical backlog in the UK is still at large, which means that there will also be periods where we see a bit more two steps forward, one step back, etc. But again, we have seen gradual improvements; Q4 confirmed that. So we remain optimistic when it comes to the UK.
Okay, that's all for me. Again, if you just look at it from Q3 to Q4 in US dollars and not taking workdays into consideration, it is a small, slight growth in Q4 to Q3.
The next question comes from Eric Cassel from Danske Bank. Please go ahead.
Hi. Good morning everyone. First, of course, everyone cares about the CERAMENT G US number and what that was organically. If I pulled the data correctly, it looked like it was up 55% organically. And I have a USD number. That was it, 21.9. Essentially, could you give any more detail on that sort of number if I'm correct in that assumption? Because that would imply an FX rate of -21%. Thank you.
Again, largely, the numbers can be recognized. We're not sharing the exact dollar numbers. Is that because we're reporting in Swedish krona? But as we shared in the presentation, you have both the absolute numbers in US dollar sales and also the average sale per working day. And again, as communicated here, we see a continued very strong and solid trend.
But the 55% organic, that seems reasonable to you, you think?
Again, if you just look at it from Q3 to Q4 in US dollars and not taking workdays into consideration, it is a small growth for Q4.
Okay, I'll leave it there, but can you talk a bit about what sort of indications have grown faster than the overall CERAMENT sales in the US, and which indications may be lagging that growth rate a bit. So we can understand what's driving this going forward.
So I think if we look at the US and CERAMENT G sales only and we look at the three segments that we are in today and actively sell into, foot and ankle, of course, is the segment where we have been the longest period of time. That's where BONESUPPORT started, really. But still, both in absolute as well as in relative terms, an important contributor to the growth of CERAMENT G. But given the size of it, and given that we've been there for a number of years, it's further on in its lifecycle, so to say. Second is trauma. And here, of course, it is a relatively new segment. You saw the numbers in terms of accounts. So that's clearly a segment that will continue to drive growth rates both short and medium term. So we're very bullish about trauma as well as we are on revision arthroplasty. So I think you can relate how long we've been in the respective segments to how much relative growth rates we can expect from them. But having said that, all three segments are very important in absolute terms for us, short and medium term. And just to be totally transparent and perhaps obvious to several of you on the call. CERAMENT G for spine is not yet approved in the US and will therefore not drive any growth in the short term. But longer term, we expect CERAMENT, once it's approved and launched in the US for spine, to be an important segment. Also in parallel to the three segments that we're already in.
Okay. Thank you. Should I read that as the osteomyelitis indication? Being a bit more matured, maybe not growing as much right now.
I wouldn't read that into it. Osteomyelitis is actually an indication that can happen in foot and ankle. It can happen in trauma, and also technically can happen in revision arthroplasty. Osteomyelitis is an underserved indication with a lot of unmet clinical need. Osteomyelitis is an underserved indication with a lot of unmet clinical need. Where CERAMENT G and V play an important role. So I would not draw that conclusion that we've reached a saturation or maturity on osteomyelitis in general. It's a very healthy and fast-growing segment for us.
Okay. Thank you. And then I just have a question on commission rates. They hit a new low here in this quarter. Does that sort of imply that fewer and fewer distributors are hitting their sort of bonus quotas. And if that's the case, could you maybe share a bit on what's required for them to get to that, I guess, 35% commission rate? This was, I think, high end and this really normalized lower. What's the difference there and how much they need to sell and grow their accounts to get different bonus levels.
So a good question, Eric. So, it sounds like an area for clarification because again, the line is defined as commission and fees and involves everything from commission to the distributors, GPO fees, credit card charges for customers paying by credit card, etc. And it's the combination of these that is down a few percentage points and so on. So it's small movements in percentage of sales; commission remains relatively stable. The commission rate, around 30%, includes certain incentives. Certain incentives if the distributors are exceeding their so-called quotas substantially. But we see very little movement in the average commission rate relative to sales. So the reason why it's down a few percentage points more relates to the other aspects of fees.
And, regarding the distributor turnover. Part of the beauty of the model we have in BONESUPPORT in the US is that we want the distributors to be on the journey with us. We want them to share the same goals. So we actively add new distributors. And when we have distributors that are not performing in line with the targets, goals, and principles that we set, we don't hesitate to phase them out. So, turnover among distributors. We've always had it, and we will continue to have that. But as Håkan said, that is not one of the reasons why we see lower commission rates. On the contrary.
Okay. Thank you. And just a last question. So far, we saw that surgical volumes per day were up a bit in Q4. Can you say anything on the sort of pace that has been now through January and February? If the daily average is roughly the same or increasing. Just so we can think about the Q1 number we could expect.
Thank you for the question. We don't comment on Q1, as you know, but similar to the many questions we received on Q4. When we released Q3, we feel confident in the journey that we're on. We feel confident in the guidance that we have set, indicating that we should grow in constant exchange rates. At least 35%. And if we see any reason to change that, we will communicate it adequately and accordingly.
All right. Thank you very much. Thank you.
The next question comes from Matthias Madsen from SEB. Please go ahead.
Hello. Good morning. I have a couple of questions as well. First one, what you shared regarding level one trauma centers 140 versus 15 as of 2024. So just if you could share some color on how important this has been while establishing the sales guidance for 2026 and, of course, also interesting to hear some insights on adoption rates in early level one trauma centers as well. That's the first one.
Sure. So, starting with your first question regarding the guidance of more than 35% growth in constant exchange rates. First of all, we have also communicated that we expect CERAMENT V to be approved by the FDA around mid this year. Of course, if we get an earlier approval and we launch earlier than that, then of course we expect to distance ourselves. More on the upside versus the 35%. However, let's say that we get late approval or no approval, then we will, of course, be close to the 35%. I think that's important to just point out that that's the role of CERAMENT V. Now when we did the guidance for 2026, there's not only one factor, of course, that we take into account. We look at growth potential across the geographies. We look at the growth potential of the different segments, and of course, trauma in the US is an important segment for us. And the data point that we have on the level one trauma centers is an important data point, as there are others as well in foot and ankle, in revision arthroplasty, in both US as well as Europe and the rest of the world. What is very important for us, and we've said this before, and it's important to continue to say. It's the balance between access and adoption that is very important. We don't want to only grow by getting new accounts. We don't only want to grow by increasing the adoption in existing accounts. We want to have a healthy balance between the two. So that's also a very important factor when we've put the guidance together. Another very important factor is when we simply recalculate the penetration, meaning the number of surgeries we are in by geography and by market segment, versus what we think is a realistic or longer-term outlook. We still believe that we have a long runway to get to what we think are perfectly realistic penetration levels. So I think it's not just the trauma number, but it's an important factor, combined with many other factors as I just described.
Good. And are you happy with what you see in terms of adoption in those level one trauma centers? Early days?
Yes. Very happy.
Then I just have a follow up on the revision arthroplasty segment that you discussed here in the presentation, which was good. Your position here and maybe how much work is yet to be done for BONESUPPORT in terms of evidence and so forth, to be able to have an ideal position for a more material contribution and a better pitch around the segment. That's my next one.
Very good. So, it's early days for us in revision arthroplasty. We have a fantastic pilot study that came out of Charité, as communicated last year. The results from that couldn't have been better, from a BONESUPPORT or a CERAMENT point of view, showing excellent results. But again, it's a pilot study and the number of patients is limited. We're building on that study going forward. And I think this is the area where, over several years, we'll need to do a lot more, which is perfectly natural. And that's part of the BONESUPPORT approach to penetrate a new market segment, meaning that we always lead with evidence. We know that our product is very innovative. It has unique capabilities in terms of its handling and in terms of how it elutes antibiotic. But we always lead with evidence. So a lot more work remains to be done. In revision arthroplasty on the evidence side. So more specific evidence. And we're working on it. We've initiated new studies and we will continue to initiate new studies in this field. However, orthopedic surgeons in general understand the unmet clinical need in the space of Revision Arthroplasty, where typically they face two challenges. Number one, how do you how do you heal the bone? How do you make sure that you grow bone in areas where you, for example, have bone voids as a result of explanting the implants in a revision situation. So having to deal with bone voids is normal and standard for revision arthroplasty. For the revision arthroplasty surgeon, we have a great solution for that with CERAMENT. Also, infections in revision arthroplasty are one of the key reasons why primary implants need to be revised. Because the patients have infections. So dealing with infections is also high on the agenda of the revision arthroplasty surgeons, and there with CERAMENT G and CERAMENT V in Europe. And hopefully, when we get the approval for CERAMENT V in the US, we have a very intuitive solution that we already see. Now surgeons are willing to try and test some of them. Surgeons actually already use it as part of their standard routine. Several surgeons want to wait until we have more evidence, but nothing is stopping us to enter this segment and penetrating this segment already now. But of course, we need more evidence. In addition to that, we believe very much in the specialization of our sales channels, meaning that a revision arthroplasty surgeon is not the same as a trauma surgeon, nor the same as a foot and ankle surgeon. So we need specialization in our go-to-market channels. So that's of course another aspect that we need to make sure that we get relevant sales channels, whether that's distributors as well as direct people, to go deeper into the respective market segments. So I hope that answers your question.
Absolutely. Good answer. My last one is fairly quick in terms of the working days that you discuss here. How many fewer working days? Was it Q4 or Q3? Was it like two days or.
It was three days shorter, was it three or four days? But I think my memory is. My memory is not skewing me, three days shorter.
Okay. Thank you very much.
The next question comes from Christopher Lilja Berg from Carnegie. Please go ahead.
Hi.
Good morning to you, I have four questions. The first one on this, sequential growth for CERAMENT G in the US seems much stronger in Q4 versus pretty weak third quarter. So could you explain, is there any particular reason for this or just natural swings between quarters? But of course, we need more evidence.
Again, as much as we refer to underlying natural swings quarter to quarter in Q3, that explanation somehow remains for Q4 because, similar to forward-looking estimates, there are several parameters that are also moving. So, I don't see any specifics. And I'm looking at Torbjörn, but I think that we share that view.
Okay, good. And the better growth in Europe, would you say that's sustainable? Just making sure there are no positive one-off larger orders or anything. Does this quarter explain the much better growth in Q4 versus what we have seen previously?
Again, what was positive to see Christopher was the improvement in the UK. It was gratifying to see what had been in our analyses also realized. But at the same time, we remain modest. We have to remain modest because again, as I mentioned in the call, the surgical backlog remains long in the UK. So there could be short periods of swings back to a slower momentum and then swing back again, etc. But again, I think we're remaining optimistic. Good to see the improvements in Q4. When we look at the investment market, as I call it now, we expect that momentum to continue when looking outside our direct markets and investments made in our so-called hybrid markets Italy, Spain, Australia, South Africa, Canada. Just to mention a few. And again, there we start from quite a low penetration level. And there is so much market potential remaining in these markets. And we believe that the investments made are a good way to capture that potential.
Okay, good. And then my third question. You mentioned the increased number of trauma centers that you are selling to, but have you reached good adoption already at some of those centers, or is that also too early to see?
No, clearly in some of them, but still, it's a very small number where we have reached a solid adoption level. But it's really early days. And, regarding the definition we use here, 'selling to' means that we've sold at least one packet of CERAMENT; of course, some early adopters engaged rapidly. We have a good adoption level, but not even close to what we think is the potential. And most of these, just do the math. Most of these trauma centers that we've sold to are still very, very early in their journey. So, yeah, we'll keep ourselves busy to increase the adoption in these level one trauma centers in the US.
Okay. Thank you. And then finally, just a clarification when it comes to guidance for 2026. So, it seems you have included very little or no V sales in the guidance.
That's correct. And that's to be prudent because we only know what we know. And although we have a great dialogue with FDA. You never know with FDA. And we follow their guidance similar to what we did now in Q4 in terms of transferring CERAMENT V from a 510(k) to a De Novo. We think that, although unexpected to us, we think it was a very good decision. Longer term for us, and it is important that we follow and deliver on what FDA wants us to. But of course, if we don't get V approved, we still believe that the 35% growth rate is definitely realistic, but it's going to be a lot easier to overdeliver if we get an early approval of V in the first half of this year.
Okay. Thank you very much.
The next question comes from Sten Gustafson from ABG Sundal Collier. Please go ahead.
Yes. Thank you. Good morning. Let's follow up on the US market penetration and adoption; to ask it in a different way, I think in the past you have shared with us a number of surgeons you have trained, and I believe—maybe I'm mistaken here—that the last number I have in my head is a thousand surgeons. I was wondering if you could update me on where you are today on that number.
Yes, those are good questions. Tim. Thank you very much. First of all, to put your question into context, this relates to all the relevant surgeons in the fields we operate in today, excluding spine. So that relates to foot and ankle trauma and revision arthroplasty. The boring part of my answer is that, no, we're not going to provide an update to that number. We don't have that routine yet. When we have that routine and when we have updated numbers that we're willing to disclose, we will, of course, do that. But having said that, we are not slowing down. We're putting a foot on the gas to accelerate, which I think we see from both the financial as well as the operational numbers, including that reference point around the major trauma centers. Because clearly, you don't really get access without training. An orthopedic surgeon.
I understand. And those level one trauma centers, on average, do they have like 50 or 100 different surgeons, or what's the size like?
It of course varies depending. I mean, in total, in the US, as per our segmentation, we have 250 level one major trauma centers. If you're a major trauma center, you're not running around with only five trauma surgeons. It's not a major trauma center, but it can vary. And I don't want to put a number out there, but it could be anything. I would only be guessing, but there are quite a number of trauma surgeons on these different centers. And our ambition in the first place is to focus on the market segments, of course, where we focus, such as foot and ankle and trauma, and then focus on the most complex, difficult cases within trauma. Where we see that CERAMENT adds the most clinical value. And then you typically start with one, maybe two surgeons and one ID doc, you start there. Only one indication or one type of case, and then you expand from there. And that's a journey that honestly can take several years. And of course, we want to do it in the right way and make sure that our product adds value to not only the orthopedic surgeon, but also the hospital and the health care system.
Makes sense. My next question would be on CERAMENT BVF and spine in particular, and I noticed a nice uptick in the change in growth trajectory for CERAMENT BVF in North America, and I was wondering how much of that is quarterly variation and how much is related to spine?
Well.
Given the fact that we initiated the launch in December on spine BVF and we tried to keep it a very focused launch in Q4. I wouldn't draw any conclusions that it is the spine launch in the US with CERAMENT BVF that made that number. The way it looks, it's more normal variations.
Okay, excellent. My final question is, India, what's the timeline looking like? What type of potential are we considering? Or should we consider for India?
Regarding India, of course. No sales in Q4 for India. When we look at India strategically long-term, it's an attractive market for a couple of reasons. The main reason is that there are many people in India. And second, there's a lot of people who are willing to pay for care in India. So the approach that we take is a very focused approach on private payers and the hospitals that serve this patient population. When we look at that patient population in terms of size, it's a sizable segment, very attractive longer term. And what we see now in India, it's first early steps, and longer term, give it a couple of years. It could be an important contributor for us. But most importantly, it's another growth leg to have in Europe and the rest of the world, because we say that a lot of times, even in Europe and the rest of the world, we're very, very early phase. We depend and have depended a lot on UK and Germany, and we've been painfully aware of that when we have had the market reforms in Germany. So adding India is an attractive segment. But again, as with all countries, it will take time. But if you count the total population and if you segment that population into how many of them do you have private insurers and how many of them have access to certain private hospitals? We feel very confident about that number. And we expect sales to start in India. Already in the first half of 2026. Sorry.
Excellent. Thank you very much. I'll get back into the queue.
The next question comes from Oscar Bergman from Redeye. I have three questions for you.
I have three questions for you. The first one, I think, is about a few ambassador sites for bone infection. Could you give sort of a ballpark figure of what percentage of relevant procedures or market penetration? Today, have they or have you become the standard of care at some of the centers in the U.S.?
Great question. To answer that last part, I would dare to say yes, but it's still only a relatively small number where we have genuinely become the standard of care. And of course, it goes to what's the definition of standard of care. And you only look at one patient indication, do you look at several, etc. So I think we're getting. Traction, clearly. One very important way to establish this for us is to look at our great collaboration with the Oxford Bone Infection Unit in the UK. And we have a fantastic collaboration and partnership with them. And one of the best ways we can educate patients in the US, or sorry, educate the surgeons in the US, is simply by sending them to Oxford and seeing how they work with it. And we see great results, including the changing of the standard of care, with a shift towards more segment use in their daily practice. But, I would say, yes, there are centers in the US that have changed their standard of care, but it's still very early days. But I don't have any hard data to share.
Okay. Do you know if those centers are typically university hospitals?
One of the key strategies in the US that we have and had for several quarters and potentially years is that we target academic medical centers. And that is simply because that's where they are very evidence and research focused. So they actually pay a lot of attention to the evidence that we have. You know that one of the key pillars in our strategy is to invest in, promote, and lead by evidence. So that's like a hand in glove with that, commercially. It's a really good way to sell and target academic medical centers because they train a lot of fellows that, when they're done training and with their fellowships, they go to somewhere else. They could go to a different academic medical center, or they could start their own practice or go somewhere else. So, definitely, our product fits very well in academic medical centers simply because it has a much higher evidence level than what's currently on the market.
Okay. And India, it's very, very interesting to hear about. I assume that the regulatory processes there are piggybacking CE marks for certainty and belief. Right?
Of course, we use the clinical data and the material that we've produced for us and used for Europe. India is a particular country with a somewhat complicated process, but the team has done a fantastic job on that. And we're getting very close to starting the launch in India in the first half of 2026.
Okay. And are there any other markets that you aim to launch in the near to medium term? I think we spoke about Japan before, very high level, of course, but it would be interesting to hear about Japan.
Japan is still on the list. It's a very attractive orthopedic market. Similar to India. Somewhat complex regulatory pathway to enter in Japan. But we're actively working on it. We've said that before also. So there's no change in that strategy. And we're getting closer to launch. But in terms of timing, India will happen before Japan.
Okay. And you also mentioned some safety inventory in the longer payment terms due to the holidays. Is it a fair assumption, then, to make that your cash flow will normalize? You're free. You're free. Free cash flow conversion should normalize already here in Q1.
And again, I think that when you look at that Oscar, it's key to see you have the same accounts receivables, but you also have accounts receivables in combination with some of the so-called K sheets that are reported as accrued revenue. So part of the increase in accounts receivables in Q4 relates to a reduction in accrued revenue or open K sheets end of Q4 compared to Q3. And the rest is simply that payments have been deferred from December to after the holidays. So with that, yes, we can expect to see the situation stabilize and normalize going into Q1. But again, the balance sheet is measured at a specific point in time. So there will always be volatility in the balance sheet. But over time as well, cash flow never lies.
Okay. Thank you.
The next question comes from Victor Sundberg from Nordea. Please go ahead.
Yes. Thanks for allowing a follow-up here. Just to follow up on your progress in trauma, one of the worries in the market with regards to trauma to us has been that maybe surgeons do not always feel the acute need to prophylactically use infection prevention in surgeries with the products, such as CERAMENT G, that comes with a bit of a price premium to older products without infection prevention. In contrast to osteomyelitis, when the infection is already always present at the intervention. So can you just comment on that as you have met more surgeons, you know, day to day at this level one centers and I've got their feedback, if this is correct or not, to look at that option in trauma in that way and maybe also quickly, the end tap here. Any more color on how the added end tap for trauma and the dropped temporary protocols will impact you with sales. When we have moved a bit into 2026, and you might have gotten a bit more data on this dynamic. Okay. Thank you.
So we'll start with the second question first for simplicity. And then we'll comment on the first one. In Q4, we did not see any material negative impact of the new law that actually came into effect 1st of October. So we don't see that we lose volume due to that. Again, early days, but in Q4, we didn't have any signals on that. I think, to your point, on trauma surgeons, regarding prophylactic use or not, we need to start even more basic in trauma, meaning when there is a very high risk of infection or a confirmed infection. That's where we start in trauma. And I don't think that we've reached any maturity or saturation on that level. Once we've done that, then of course, it comes to prophylaxis. Prophylactically, of course, is always more challenging than the starting point. But once you get the starting point right, my experience is that when that is achieved and surgeons understand and see the value that CERAMENT has, then moving into that prophylactic stage becomes more natural. And different surgeons, different clinics, different centers are in different parts of this journey. But I would argue that prophylaxis is still further out. But we're making really good progress by starting with the basics and getting them to be aware and understand the role of CERAMENT in these type of cases.
Okay, thanks.
There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.
No. With that, thank you all for your interest. And we wish you all a great rest of the day. No. With that, thank you all for your interest.



















